药品定价与风险分担

导出

摘要最近,一些国家开始把风险分担协议应用于药品定价中。本文提出了一个包含药品效果(effectiveness)变量的风险分担协议,并说明了这个机制在长期如何影响市场。本文还特别说明监管者是如何应用这个定价机制在所期望的疗效与接受该药品治疗的患者数量之间做出权衡的。

作者 Stefano Capri Rosella Levagg 林琳汤涵

机构地区意大利degli Studi di Brescia大学

出处《中国药物经济学》 2009年第2期83-86,共4页 China Journal of Pharmaceutical Economics

关键词疗效效果药品定价风险分担上市

参考文献5

1Zaric GS,O‘ Brien BJ.Analysis of a pharmaceutical risk sharing agreement based on the purchaser‘ s total budget(J)[].Journal of Health Economics.2005
2Pirmohamed M,Lewis G.The Implications of Pharmacogenetics and Pharmacogenomics for Drug Development and Health Care[].Regulating Pharmaceuticals in Europe:Striving For EfficiencyEquity and Quality(M).2004
3NICE.Final Appraisal Determination:Bortezomib monotherapy for relapsed multiple myeloma(R)[]..2007
4Barro PP.The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry(M)[]..2007
5Claxton K,Briggs A,Buxton M J,Culyer A J,McCabe C,Walker S,Sculpher MJ.Value based pricing for NHS drugs:an opportunity not to be missed(J)[].British Medical Journal.2005

中国药物经济学

2009年第2期

内容加载中请稍等...